drugset / Trial / NCT05163652
Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and Above
Phase 3
Unknown
432 enrolled
Chinese Academy of Medical Sciences
Yunnan Center for Disease Control and Prevention · collab
Non-randomizedSingle-groupOpen-labelPrevention
Summary
To evaluate the immunogenicity and safety of the third dose SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above, who inoculated the third dose after 3, 4, 5, or 6 months since finished two doses schedule of CoronaVac or BBIBP-CorV.
Timeline
- Start
- 2021-12-18
- Primary completion
- 2022-08-30
- Completion
- 2022-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SARS-CoV-2 Vaccine, Inactivated (Vero Cell) | Vaccine | — | — |